The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CRIS | -70.36% | -93.31% | -41.77% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +368% |
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
The biotech's shares rode the wave of buyout speculation higher last month.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.75M | 8.0% |
| Gross Profit | $2.69M | 8.9% |
| Gross Margin | 97.89% | 0.8% |
| Market Cap | $24.27M | -40.3% |
| Market Cap / Employee | $0.71M | 0.0% |
| Employees | 34 | -30.6% |
| Net Income | -$8.59M | 27.2% |
| EBITDA | -$8.21M | 34.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.14M | 1.4% |
| Accounts Receivable | $2.75M | 8.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $23.85M | -24.9% |
| Short Term Debt | $8.62M | -15.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -97.73% | -27.1% |
| Return On Invested Capital | -74.54% | -16.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.01M | 28.1% |
| Operating Free Cash Flow | -$8.01M | 28.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -45.86 | -2.11 | -2.97 | -3.67 | -185.47% |
| Price to Sales | 3.12 | 2.15 | 1.59 | 2.57 | -34.99% |
| Price to Tangible Book Value | -3.29 | -1.04 | -1.19 | -1.56 | -101.84% |
| Enterprise Value to EBITDA | -4.80 | -4.52 | -3.16 | -6.29 | 45.79% |
| Return on Equity | -372.7% | -436.2% | -634.7% | -2951.2% | 1323.74% |
| Total Debt | $39.25M | $37.13M | $34.35M | $32.47M | -22.55% |
CRIS earnings call for the period ending June 30, 2022.
CRIS earnings call for the period ending March 31, 2022.
CRIS earnings call for the period ending December 31, 2021.
CRIS earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
